CD36 and breast carcinoma: Indeed, the mevalonate precursor enzyme HMGCS1 is a marker of CSC enrichment in breast cancer (Biddle et al, 2011), whereas CD36, the receptor for the palmitic acid, is overexpressed in CD44-positive metastasis-initiating cells in oral squamous cell carcinoma (Pascual et al, 2017).